BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 28725988)

  • 21. Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.
    Chiavazza C; Pellerino A; Ferrio F; Cistaro A; Soffietti R; Rudà R
    Biomed Res Int; 2018; 2018():3606970. PubMed ID: 30035121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.
    Birsen R; Blanc E; Willems L; Burroni B; Legoff M; Le Ray E; Pilorge S; Salah S; Quentin A; Deau B; Franchi P; Vignon M; Mabille L; Nguyen C; Kirova Y; Varlet P; Edjlali M; Dezamis E; Hoang-Xuan K; Soussain C; Houillier C; Damotte D; Pallud J; Bouscary D; Tamburini J
    Oncotarget; 2018 Mar; 9(24):16822-16831. PubMed ID: 29682187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
    J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
    Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interim
    Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Park JS; Ryu JS; Huh J; Park CS; Kim JH; Lee SW; Suh C
    Ann Hematol; 2017 Sep; 96(9):1509-1515. PubMed ID: 28725988
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review.
    Adams HJA; Nievelstein RAJ; Kwee TC
    Ann Hematol; 2016 Jan; 95(1):11-18. PubMed ID: 26576560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.
    Song Y; Wen Y; Xue W; Zhang Y; Zhang M
    Int J Hematol; 2017 Nov; 106(5):612-621. PubMed ID: 28900847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary Suprasellar Hypothalamic CNS Lymphoma in an Immunocompetent Adult: A Case Report and Review of Literature.
    Mohanty CB; Muley KD; Deopujari CE
    Neurol India; 2020; 68(6):1435-1438. PubMed ID: 33342884
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.